Tat-D3S2

Tat-D3S2

Catalog Number:
P004516713LIF
Mfr. No.:
PEPTIDE-PP-340
Price:
$386
  • Size:
    1mg
    Quantity:
    Add to Cart:
      • Overview
        • DIRAS3 – beclin1 interaction inhibitor.
          Tat-D3S2 is a peptide derived from the sequence of the switch II region of the small GTPase DIRAS3, conjugated with the HIV-1 Tat protein transduction domain to enhance cellular permeability. DIRAS3 can induce autophagy and plays an important role in forming the autophagosome initiation complex (AIC) with beclin1. In disease states autophagy can protect cancer cells from acute starvation and enhance resistance to chemotherapy. Due to similarity to the binding region of DIRAS3, Tat-D3S2 can bind to beclin 1 and inhibit the beclin1 – DIRAS3 interaction necessary for the induction of autophagy, and in ovarian cancer cells where autophagy is induced by amino acid deprivation, Tat-D3S2 significantly inhibits cell viability.

          Please contact us for availability.

          Please contact us at for specific academic pricing.

      • Properties
        • Categories
          Cell Penetrating Peptides
          Alternative Name
          DIRAS3 switch II-derived peptide, TatD3S2
          Molecular Formula
          C144H255N65O39
          Molecular Weight
          3521.02
          Appearance
          Freeze dried solid
          Purity
          >95% by HPLC
          Solubility
          Soluble in water
          Other Properties
          Sequence: H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Gly-Ser-Lys-Ser-Gly-Asp-Gly-Asn-Arg-Ala-Leu-Gln-Arg-His-Val-Ile-Ala-Arg-OH,YGRKKRRQRRRGGSKSGDGNRALQRHVIAR
          Storage
          Store dry, frozen and in the dark

          * Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.

    We Also Recommend

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.